Actively Recruiting
Comparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease
Led by University of Wisconsin, Madison · Updated on 2026-04-24
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research study focuses on inherited retinal diseases (IRDs) and aims to compare two ultrawide field imaging cameras, Clarus and Optos, against the standard Spectralis imaging system. The goal is to determine if all these cameras provide the same results and information for evaluating and monitoring IRDs. The study is sponsored by the University of Wisconsin, Madison, and involves adult participants diagnosed clinically or genetically with IRD. Participants will undergo pupillary dilation followed by photographs taken of the inside of their eyes using three different camera systems: Spectralis FAF imaging, Optos imaging, and Clarus imaging. Spectralis captures 20-55 degrees of the retina using blue light, while Optos and Clarus provide ultrawide field images covering up to 200 degrees with different light excitation methods. During the study visit, researchers will compare fundus autofluorescence (FAF) retinal patterns across the three cameras and evaluate abnormalities unique to IRD. Each imaging session lasts up to 2 hours. The study measures how well the ultrawide field cameras capture retinal changes beyond the standard imaging field and assesses other autofluorescence abnormalities. Participants are monitored for their ability to tolerate imaging, and the study takes place over a single visit.
CONDITIONS
Brief Title
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants 18 years and older with a clinical and/or genetic diagnosis of inherited retinal disease
- Participants willing to participate and able to provide written informed consent
You will not qualify if you...
- Presence of other eye conditions that may affect the quality of imaging such as advanced cataracts, corneal disorders, nystagmus, vitreous hemorrhage, or poor pupil dilation
- Presence of other eye conditions that may affect interpretation of retinal imaging including epiretinal membrane, choroidal neovascular membrane, or macular scarring
- Patients with advanced inherited retinal diseases who cannot keep their eyes steady for imaging
- Patients unable to tolerate eye imaging
- Patients who do not wish to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 hours
Participants undergo imaging using Clarus, Optos, and Spectralis devices to capture retinal autofluorescence patterns.
1 imaging visit (in-person)
Trial Site Locations
Total: 1 location
1
Department of Ophthalmology and Visual Sciences
Madison, Wisconsin, United States, 53705
Actively Recruiting
Research Team
A
Angie Adler
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here